Skip to main navigationSkip to main content
The University of Southampton
Medicine

Professor Peter Johnson CBE MD FRCP FMedSci

Professor of Medical Oncology

Professor Peter Johnson's photo
Related links

Professor Peter Johnson is Professor of Medical Oncology within Medicine at the University of Southampton.

Peter Johnson graduated from Cambridge University and St Thomas's Medical School. He trained in oncology at St Bartholomew's Hospital, where he was an Imperial Cancer Research Fund Clinical Research Fellow and completed his doctoral research on the Bcl-2 gene, its potential as a therapeutic target in lymphoma and the effects of CD40 ligation on the B-cell surface. He was subsequently a Senior Lecturer in Medical Oncology in the ICRF Cancer Medicine Research Unit, Leeds and took up the Chair of Medical Oncology in Southampton in 1998. He leads the Southampton Cancer Research UK Centre, responsible for bringing together a broad multidisciplinary group of basic, translational and clinical researchers, and linking the laboratory research to the extensive clinical practice in cancer treatment in the Southampton Cancer Centre. Southampton hosts an Experimental Cancer Medicine Centre and a Clinical Trials Unit, both with core support from NIHR and CR UK. He was Chief Clinician for Cancer Research UK from 2008-2017, and since 2018 has been Director the Francis Crick Institute cancer research network.

 

Qualifications

BA, University of Cambridge 1982
MB BChir, University of Cambridge 1985
MA,University of Cambridge 1986
MRCP, Royal College of Physicians 1988
MD, University of Cambridge 1994
FRCP, Royal College of Physicians 1998

Appointments held

House Physician, St Thomas’s Hospital, London. 1986
SHO rotations in General Medicine, Guy’s & St Bartholomew’s Hospitals, London. 1986-1988
Registrar in General Medicine, Frimley Park Hospital, Surrey. 1988-1989
Registrar in Medical Oncology & ICRF Clinical Research Fellow, St Bartholomew’s, London. 1989-1994
Senior Lecturer in Medical Oncology, University of Leeds. 1994-1988
Prof of Medical Oncology, Faculty of Medicine, University of Southampton 1998 to current
Honorary Consultant in Medical Oncology, Southampton University Hospitals NHS Trust 1998 to current

Research interests

Peter Johnson specialises in the treatment of lymphoma, and is the Chief Investigator for several lymphoma trials nationally and internationally.

He works closely with the immunologists of the academic group, in particular for basic and translational research into the use of immunostimulatory antibodies. He is the Chief investigator in a phase I clinical trial of an agonistic chimerised anti-CD40 antibody which was developed with the antibody research group, and which has been used to test the idea that CD40 ligation may be able to enhance antigen presentation via licencing of professional APCs, while at the same time directing killing of CD40+ tumour cells.

His recent international trials include the RATHL study in advanced Hodgkin lymphoma, investigating the use of FDG-PET scanning to guide treatment intensification or de-escalation, to optimize the balance between efficacy and toxicity. He also led the REMoDL-B study, the first to use gene expression profiling in real time to stratify treatment for diffuse large B-cell lymphoma.

 

Department(s)

Cancer Sciences

Affiliate Department(s)

Cancer Sciences Research group

National Responsibilities
Francis Crick Institute, Scientific Management Committee
Royal College of Physicians, Joint Specialist Committee on Medical Oncology, Chair
Genomics England Ltd Scientific Advisory Committee 2013-2016
National Cancer Research Institute, Clinical and Translational Steering Group, Chair 2013-2017
Academy of Medical Sciences Review of Research Governance and Regulation 2010-2011
NHS Chief Executive Review of Innovation 2011
Department of Health Human Genome Strategy Group 2010-2011
Department of Health Cancer Diagnostics Advisory Board 2009-2013
Chief Clinician, Cancer Research UK 2008-2017
Research Assessment Exercise 2008, UoA 3 Sub-panel 02 (Cancer) 2008
National Cancer Research Institute, Board 2008-2015
National Cancer Research Institute, Lymphoma Clinical Studies Group (Chair 2005-2011)
MRC/CR UK Clinical Trials Advisory and Awards Committee 2002-2004
NHS Executive Cancer Clinical Outcomes Group, Haematologic Malignancy 2001-2003
Leukaemia Research Fund, Clinical Trials Advisory Panel 2001-2005
Medical Research Council, Trial Steering Group for Gastrointestinal and Gynaecologic Malignancy 2000-2008
Association for International Cancer Research, Scientific Advisory Committee 2000-2003

International Responsibilities
International Conference on Malignant Lymphoma, Organising Committee
International Symposium on Hodgkin Lymphoma, Scientific Committee
Schweiz. Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK), International advisor
Swiss Institute for Experimental Cancer Research, Scientific Board
Cancer Immunotherapy (CIMT) Consortium, Executive Board

Scientific Advisory Boards
Carrick Therapeutics
Oncimmune

 

 
Sort via:TypeorYear

Articles

Book Chapters

  • Cummin, T., Cragg, M., Friedberg, J. W., & Johnson, P. (2019). Targeted therapeutics for lymphoma: Using biology to inform treatment. In G. Lenz, & G. Salles (Eds.), Agressive Lymphomas (1 ed., pp. 343-360). (Hematologic Malignancies). Cham: Springer.
  • Younes, A., Dogan, A., Johnson, P., Yahalom, J., Kuruvilla, J., & Ansell, S. (2018). Hodgkin lymphoma. In DeVita, Hellman, and Rosenberg's Cancer: principles & practice of oncology (11th ed., pp. 1649-1671). Wolters Kluwer.

Letters/Editorials

Reviews

Personal tutor

Clinical attachments for final year BM5 students

PhD Training account for Clinical Research Fellows

 

Postgraduate Student Supervision
22 successfully completed since 1999
2 in progress

Professor Peter Johnson
Centre for Cancer Immunology
University Hospital Southampton (MP 127)
Tremona Road
Southampton SO16 6YD

Tel: 023 8120 6186
Email: johnsonp@soton.ac.uk
Twitter: @pwmjohnson

Room Number: SGH/CCI/1045/MP127/MP824

Share this profile Share this on Facebook Share this on Twitter Share this on Weibo
Privacy Settings